Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anticancer Therapy
Farnesyltransferase inhibitor ABT-100 overwhelms cancer growth signal
June 6th, 2005
Farnesyltransferase inhibitor ABT-100 overwhelms cancer growth signals. In a recent study, scientists in the United States conducted research "to evaluate the preclinical pharmacokinetics, antitumor efficacy, and mechanism of action of a novel orally active farnesyltransferase inhibitor, ABT-100." "In vitro sensitivity of a panel of human cell lines was determined using proliferation and clonogenic assays. In vivo efficacy of ABT-100 was evaluated in xenograft models (flank or orthotopic) by assessing angiogenesis, proliferation, and apoptosis in correlation with pharmacokinetics. Efficacy of the racemate of ABT-100 (A-367074) was also compared with...
Source: Biotech Business Week (2005-06-06)
|
